Table 3.
Values of Spearman correlation test and significance level (p) between clinical and laboratory parameters with age, duration of use, and dose of risperidone in the study sample.
| Parameters | ChronologicAge (years) | Bone age (years) | Length of risperidone use (months) | Risperidone dose (mg) | Dose (mg) per kilogram of body weight |
|---|---|---|---|---|---|
| BMI | −0.015 (0.872) |
0.017 (0.851) |
0.026 (0.781) |
0.090 (0.327) |
−0.217 (0.017) |
|
| |||||
| WC (cm) |
0.395
(0.0001) |
0.409
(0.0001) |
0.030 (0.746) |
0.217
(0.017) |
−0.151 (0.100) |
|
| |||||
| SBP (mmHg) |
0.487
(0.0001) |
0.501
(0.0001) |
0.202 (0.027) |
0.203
(0.027) |
−0.080 (0.386) |
|
| |||||
| DBP (mmHg) |
0.335
(0.0001) |
0.308
(0.001) |
0.176 (0.055) |
0.126 (0.169) |
−0.041 (0.658) |
|
| |||||
| Total cholesterol (mg/dL) | −0.008 (0.928) |
−0.051 (0.580) |
−0.068 (0.462) |
0.119 (0.194) |
0.075 (0.415) |
|
| |||||
| LDL cholesterol (mg/dL) | 0.057 (0.537) |
−0.007 (0.940) |
−0.037 (0.687) |
0.075 (0.414) |
0.008 (0.932) |
|
| |||||
| HDL cholesterol (mg/dL) | −0.171 (0.062) |
−0.183
(0.046) |
−0.138 (0.133) |
0.024 (0.791) |
0.120 (0.193) |
|
| |||||
| Triglycerides (mg/dL) | 0.126 (0.170) |
0.147 (0.108) |
−0.023 (0.806) |
0.115 (0.213) |
−0.25 (0.784) |
|
| |||||
| HOMA-IR index | 0.169 (0.065) |
0.185
(0.043) |
0.021 (0.818) |
0.088 (0.340) |
−0.092 (0.320) |
|
| |||||
| AST (U/L) |
−0.322
(0.0001) |
−0.283
(0.002) |
0.009 (0.925) |
−0.070 (0.450) |
0.043 (0.644) |
|
| |||||
| ALT (U/L) | 0.019 (0.840) |
0.017 (0.858) |
−0.023 (0.801) |
0.100 (0.277) |
−0.013 (0.889) |
|
| |||||
| Leptin (pg/mL) | 0.113 (0.217) |
0.087 (0.345) |
−0.045 (0.624) |
−0.012 (0.898) |
−0.257
(0.005) |
WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure.